142 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
toxicities, in line with previous findings indicating an acceptable safety profile.
ADP-A2M4CD8 – Adaptimmune’s next-generation product … from 1.18+ to 16.6+ months and 12 out of 18 patients were censored for this analysis.
Overall, the safety profile of lete-cel was acceptable, including
8-K
EX-99.1
us4t0l oj3zynpbt3
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
1kt5xtuyc6y3
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K
EX-10.1
balkuqc76b0e82iif
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
h3y2b
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
w198n gsgsit
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
0grpjuctgc xh4
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
kovpsphh0p84 ql0k
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
vhup5
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am